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 Summary
  Fahr syndrome is a rare neurodegenerative disorder characterized by symmetrical, bilateral 
calcifications in the basal ganglia, nucleus gyrus and cerebral cortex. The continuous advancement 
as well as widespread use of brain imaging have contributed to the increasing detection rates 
of such changes. Nevertheless, their etiology is understood only partially and the methods of 
causative treatment are limited. Due to various symptoms, Fahr syndrome may resemble diseases 
from the field of neurology, psychiatry, cardiology and even urology. This article provides an up-to-
date review of the literature concerning Fahr syndrome in terms of clinical practice.
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In 1930, a German pathologist, Karl Theodor Fahr, 
described a case of a man with symmetrical calcifications 
of the basal ganglia and cerebral cortex [1]. The syndrome, 
named after this author, manifests with a wide range of 
neurological as well as psychiatric symptoms. The patho-
genesis and clinical presentation of Fahr syndrome, known 
also as bilateral striatopallidodentate calcinosis (BSPDC) or 
Chavany-Brunhes syndrome, are partially understood, but 
there is still a lot to be discovered [2].
Etiology
Fahr syndrome is characterized histologically by foci of 
symmetrical, non-atheromatic compounds embedded in a 
protein-polysaccharide complex that are located within the 
globus pallidus, striatum, dentate nucleus, basal ganglia 
as well as within white and gray matter of the brain and 
cerebellum [2]. The deposits consist of calcium, zinc, iron, 
aluminum, magnesium, silicon, copper and phosphorus [3]. 
There are significant differences in the distribution of cal-
cifications between individual patients. This may indicate 
the different mechanisms of their formation. The location 
within the brain structures as well as contact with blood 
vessel are the most important factors determining the 
chemical composition of the deposits. On this basis, two 
types of mineralization were described, non-vascular and 
perivascular [4].
Some reports describe the inheritance of Fahr syndrome, 
mainly in an autosomal dominant way. So far, four genes 
have been proved to be related to primary familial brain 
calcification; namely, SLC20A2, PDGFRB, PDGFB and 
XPR1 [5–12]. However, in the majority of patients, the syn-
drome does not have a genetic background. Bilateral basal 
ganglia calcifications can be observed in disorders of cal-
cium and phosphorus metabolism, especially in hypopar-
athyroidism. However, the frequency of their occurrence 
is low [13,14]. Ku1czycki et al. distinguished the following 
three types of biochemical abnormalities of calcium-phos-
phate homeostasis:
1.  True hypoparathyroidism (low calcium and high phos-
phate serum concentration, increased cAMP and phos-
phate excretion in urine after stimulation with parathy-
roid hormone);
2.  Pseudohypoparathyroidism (low calcium and high phos-
phate serum concentration, no increase in the excretion 
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of cAMP and phosphate in urine after stimulation with 
parathyroid hormone);
3.  Calcifications co-existing with normal serum calcium 
and phosphate levels, a significant increase in the excre-
tion of cAMP after stimulation with parathyroid hor-
mone and its relatively low phosphaturic effect [15,16].
According to Pronicka et al., resistance to parathyroid hor-
mone may play a key role in some individuals with Fahr’s 
syndrome. It is manifested by a decreased phosphatu-
ric effect of this hormone, while cAMP excretion in urine 
remains within a normal range. Interestingly, this response 
can be improved by beta-blockers, suggesting that Fahr’s 
syndrome may be a result of a defect of adrenergic recep-
tors and their impaired relationship with parathyroid hor-
mone receptors [17]. Another biochemical abnormality 
observed in Fahr’s syndrome is an increased alkaline phos-
phatase activity in the basal ganglia of the brain, while its 
level in serum remains normal. These changes may pro-
mote a precipitation of insoluble calcium phosphate salts 
in the nervous tissue [18]. In up to one-third of patients 
with Fahr’s syndrome, a close relationship between cal-
cifications and impaired cerebral blood flow can be dem-
onstrated [19]. Such patients present cerebral circulatory 
disturbances in the form of transient ischemic attacks or 
strokes. Perivascular positioning of calcifications may sug-
gest aberrant function of adventitia that could predispose 
to blood-brain barrier damage and deposition of calcium 
compounds. A major argument in favor of a vascular the-
ory was given by the studies using brain flow scintigraphy 
that provided evidence of an impaired blood flow in cal-
cification sites [20]. Moreover, inflammatory conditions, 
e.g. meningitis or encephalitis, are taken into account 
when considering the pathogenesis of Fahr’s syndrome [21]. 
Coexistence of Fahr’s syndrome with lupus erythemato-
sus, monoclonal gammopathy and brain tumors, such as 
astrocytoma or pineal body gangliocytoma, was described 
in some case reports [22–25]. A significant role in the dis-
cussed processes may be attributed to homocarnosine, a 
specific antioxidant dipeptide found in the central nervous 
system. It is believed that the inhibition of calcification for-
mation within subcortical structures is a task of homocar-
nosine [2].
The presented data do not encompass all clinical situa-
tions leading to the formation of intracranial calcification. 
Calcifications occur more often in elderly patients and 
may be symptoms of many diseases such as toxoplasmosis, 
cytomegalovirus, syphilis, tuberculosis, torulopsis, cyst-
icercosis, tuberous sclerosis and others [26,27]. It is worth 
mentioning that calcifications are quite commonly found 
in clinical practice and may be encountered as physiologi-
cal calcifications in the pineal gland or choroid plexuses as 
well as on the walls of blood vessels.
Clinical Presentation
Fahr’s syndrome has an insidious, slow and progressive 
course. The symptoms usually occur between the fourth 
and sixth decade of life, but they have been also reported in 
children as well as in young adults [28]. The clinical pres-
entation varies depending on the time of onset. Thus, three 
forms of the syndrome were distinguished:
1.  Early childhood onset – characterized by inhibition of 
mental development and early mortality;
3.  Early onset (approximately at the age of 30) – character-
ized by psychiatric symptoms;
3.  Late onset (approximately at the age of 50) – character-
ized by progressive dementia and movement disorders 
[29–32].
The most common symptoms of Fahr’s syndrome in 
adults include parkinsonism, dystonia, ataxia, chorea and 
extrapyramidal syndromes. Some patients may present 
with seizures and pyramidal disorders [33,34]. Psychiatric 
symptomatology typically includes cognitive impairment, 
schizophrenia-like psychosis, hallucinations, delusions, 
anxiety, mania, depression, hyposchemazia as well as per-
sonality changes [35–38]. Headache, vertigo, stroke-like 
events, orthostatic hypotension, dysarthria, paresis, over-
active bladder and syncope of unknown etiology have also 
been reported [39–41]. In children, Fahr’s syndrome may 
take the form of severe encephalopathy with dwarfism, 
microcephaly and optic nerve atrophy [28]. The patients 
who are under our observation complained of memory 
impairment, dyskinesia, recurrent loss of consciousness 
and urinary incontinence. It should be emphasized that 
only a small percentage of people with intracranial calcifi-
cations are symptomatic. In most cases, it is an accidental 
discovery without any clinical implications.
Diagnosis
Although the first radiographic descriptions appeared more 
than 50 years ago, a broad availability of computed tomog-
raphy (CT) was a cornerstone for the detection of intracra-
nial calcifications and increased the number of diagnosed 
Fahr’s syndrome cases [42]. Currently, CT is the most valu-
able method that surpasses magnetic resonance imaging 
(MRI) (Figure 1A, 1B) [43,44]. Toscano et. al. suggested that 
transcranial sonography can be a useful tool in imaging 
basal ganglia calcinosis [45]. Differential diagnosis is ham-
pered significantly by the lack of precise criteria. In that 
respect, it is important to detect calcification foci greater 
than 800 mm2 in surface area, regardless of their number 
[46]. Electroencephalography has a low diagnostic value, 
because all kinds of alterations in the central electrophysi-
ological activity are possible [47]. Thus, neurological and 
psychological examinations as well as CT imaging remain 
the basic techniques for the diagnosis of Fahr’s syndrome.
The following diagnostic criteria were established:
1.  Bilateral calcifications of the basal ganglia or other areas 
of brain on neuroimaging (may not apply to patients 
from families with Fahr’s syndrome);
2.  Progressive neurological dysfunction and/or psychiatric 
symptoms;
3.  Onset between the ages of 40–50;
4.  Absence of biochemical abnormalities and somatic states 
suggestive of a metabolic or mitochondrial disease;
5.  Absence of toxic, infectious or traumatic causes of 
intracranial calcifications;
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If a patient meets the last criterion, the diagnosis can be 
made without the presence of one of the first two criteria. 
In cases of a negative or unknown family history, other five 
criteria must be fulfilled [48–51]. Not all intracranial calci-
fications point towards Fahr’s syndrome. Calcium deposits 
with a thin, linear or cloudy pattern have a high-specificity. 
On the other hand symmetric micronodular or asymmetric 
unilateral calcifications are not characteristic of this dis-
ease [51].
Treatment
In most cases, treatment is symptomatic and includes 
antipsychotics, antidepressants, antiepileptic and pro-
cognitive drugs. A distinctive feature of parkinsonian syn-
dromes with concomitant calcifications is an outstanding 
resistance to the therapy with levodopa. This disorder more 
likely results from insensitivity of postsynaptic striatal 
structures rather than presynaptic damage observed in the 
primary parkinsonism [52].
Conclusions
Fahr’s syndrome has a rare radiological presentation of 
bilateral calcifications in the basal ganglia, nucleus gyrus 
and cerebral cortex. It may coexist with many symptoms 
resembling the diseases from the field of neurology, psy-
chiatry, cardiology as well as urology. From a practical 
point of view, the most important issue is to differentiate 
the symptomatic and asymptomatic cases of Fahr’s syn-
drome and to detect abnormalities of calcium metabolism, 
primarily hypoparathyroidism, because their correction is 
the only causative treatment that can significantly improve 
symptoms and prognosis.
Figure 1.  Bilateral calcifications in the basal ganglia and cerebellum found on computed tomography.
A B
 1. Fahr T: Idiopathische Verkalkung der Hirngefässe. Zentralbl Allg 
Pathol, 1930; 50: 129–33 [in German]
 2. Manyam BV, Bhatt MH, Moore WD et al: Bilateral striopallidodentate 
calcinosis: Cerebrospinal fluid, imaging and electrophysiological 
studies. Ann Neurol, 1992; 31: 379–84
	 3.	Kuran	W,	Kozik	M,	Ku1czycki	J:	Analiza	laserowa	złogów	
rzekomowapniowych w zespole Fahra. Neurol Neurochir Pol, 1981; 
4: 397–401 [in Polish]
 4. Bouras C, Giannakopoulous P, Good PF et al: A laser microprobe mass 
analysis of trace elements in brain mineralisations and capillaries in 
Fahr’s disease. Acta Neuropathol, 1996; 92: 351–57
 5. Arts FA, Velghe AI, Stevens M et al: Idiopathic basal ganglia 
calcification-associated PDGFRB mutations impair the receptor 
signalling. J Cell Mol Med, 2015; 19: 239–48
 6. Chen WJ, Yao XP, Zhang QJ et al: Novel SLC20A2 mutations 
identified in southern Chinese patients with idiopathic basal ganglia 
calcification. Gene, 2013; 529: 159–62
 7. Hayashi T, Legati A, Nishikawa T, Coppola G: First Japanese family 
with primary familial brain calcification due to a mutation in the 
PDGFB gene: An exome analysis study. Psychiatry Clin Neurosci, 
2015; 69: 77–83
References:
 8. Lemos RR, Ramos ME, Legati A et al: Update and mutational 
analysis of SLC20A2: A major cause of primary familial brain 
calcification. Hum Mutat, 2015; 36(5): 489–95
 9. Oliveira JR, Spiteri E, Sobrido MJ et al: Genetic heterogeneity 
in familial idiopathic basal ganglia calcification (Fahr disease). 
Neurology, 2004; 63: 2165–67
 10. Sanchez-Contreras M, Baker MC, Finch NA et al: Genetic screening 
and functional characterization of PDGFRB mutations associated 
with basal ganglia calcification of unknown etiology. Hum Mutat, 
2014; 35: 964–71
 11. Taglia I, Mignarri A, Olgiati S et al: Primary familial brain 
calcification: Genetic analysis and clinical spectrum. Mov Disord, 
2014; 29: 1691–95
	 12.	Anheim	M,	López-Sánchez	U,	Giovannini	D	et	al:	XPR1	mutations	
are a rare cause of primary familial brain calcification. J Neurol, 
2016; 263(8): 1559–64
 13. Koller WC, Cochran JW, Klawans HL: Calcification of the basal 
ganglia. Computerized tomography and c1inical correlation. 
Neurology, 1979; 29: 328–33
 14. Puvamendram K, Low CH, Boey HK, Tan KP: Basal ganglia 
calcification on computer tomographic scan. Acta Neurol Scand, 
1982; 66: 309–15
Jaworski K. et al. – Fahr syndrome – diverse manifestations of basal ganglia…
492
© Pol J Radiol, 2017; 82: 490-493
	 15.	Kulczycki	J,	Pronicka	E,	Rowińska	E	et	al:	Udział	przytarczyc	w	
patogenezie	zwapnień	śródmózgowiowych.	Neurol	Neurochir	Pol,	
1987; 2: 112–18 [in Polish]
 16. el Maghraoui A, Birouk N, Zaim A et al: Fahr syndrome and 
dysparathyroidism. 3 cases. Presse Med, 1995; 24: 1301–4
	 17.	Pronicka	E,	Kulczycki	J,	Rowińska	E,	Kuran	W:	Abolished	
phosphaturic response to parathormone in adult patients with 
Fahr’s disease and its restoration after propranolol administration. J 
Neurol, 1988; 235: 185–87
 18. Brannan TS, Burger AA, Chaudhary MY: Bilateral basal ganglia 
calcifications visualised on CT scan. J Neurol Neurosurg Psychiatry, 
1980; 43: 403–6
	 19.	Bartecki	BF,	Kamieniowski	J:	Zwalniające	niedokrwienie.	Ogniskowe	
w przypadkach choroby Fahra. Neurol Neurochir Pol, 1979; 4: 443–
47 [in Polish]
 20. Uygur GA, Lin Y, Hellman RS, Tikofsky RS: Evaluation of regional 
cerebral blood flow in massive intracerebral calcification. J Nucl 
Med, 1995; 36: 610–12
 21. Bobek J, Nowak M: Familial form of Fahr syndrome (report of two 
cases). Neurol Neurochir Pol, 2000; 34: 167–75
 22. Ang LC, Rozdilsky B, Alport EC, Tchang S: Fahr’s disease associated 
with astrocytic proliferation and astrocytoma. Surg Neurol, 1993; 39: 
365–69
 23. Chang RS, Chun-Yin LW, Leong HS: Bilateral striatopallidodentate 
calcinosis associated with systemic lupus erythematosus: Case report 
and review of literature. J Neurol Sci, 2015; 358(1–2): 518–19
 24. Nishiyama K: [A case of idiopathic, symmetrical naoarteriosc1erotic 
intracerebral calcification (Fahr’s disease) associated with 
M-proteinemia, followed by multiple myeloma.] Rinshko 
Shihkeigaku, 1991; 31: 781–89 [in Japanese]
 25. Toroto K, Chiba Y, Ohtani T et al: Pineal ganglioma in a patient 
with familial basal ganglia calcification and elevated serum alpha-
fetoprotein; Case report. Neurosurgery, 1993; 33: 506–11
 26. Yamada M, Asano T, Okamoto K et al: High frequency of calcification 
in basal ganglia on brain computed tomography images in Japanese 




 28. Billard C: Encephalopathy with calcifications of the basal ganglia 
in children. A reappraisal of Fahr syndrome with respect to 14 new 
cases. Neuropediatrics, 1989; 20: 12–15
 29. Babbit DP, Tang T, Dobbs J: Idiopathic familiar cerebrovascular 
ferrocalcinosis (Fahr disease) and review of differential diagnosis of 
intracranial calcification in children. Am J Roentgenol Radium Ther 
Nuc Med, 1969; 105: 352–58
 30. Cummings JL, Gosendfeld LF, Houlihan JP: Neuropsychiatric 
disturbances associated with idiopathic calcification of the basal 
ganglia. Biol Psychiatry, 1983; 18: 591–601
 31. Francis AF: Familial basal ganglia calcification and schizophreniform 
psychosis. Br J Psychiatry, 1979; 13: 360–62
 32. Modrego PJ, Mojonero J, Serrano M, Fayed N: Fahr’s syndrome 
presenting with pure and progressive presenile dementia. Neurol Sci, 
2005; 26: 367–69
 33. Hoque MA, Siddiqui MR, Arafat Y et al: Fahr’s disease: A very rare 
cause of epilepsy. Mymensingh Med J, 2010; 19: 127–29
 34. Matsui K, Yamada M, Kobayashi T et al: [An autopsy case of Fahr 
disease (infantile form).] No To Hattatsu, 1992; 24: 358–63 [in 
Japanese]
 35. Casamassima F, Lattanzi L, Perlis RH et al: Efficacy of 
electroconvulsive therapy in Fahr disease associated with bipolar 
psychotic disorder: A case report. J ECT, 2009; 25: 213–15
 36. Munir K: The treatment of psychotic symptoms in Fahr’s disease 
with lithium carbonate. J Clin Psychopharmacol, 1986; 1: 35–38
 37. Wertele J, Rybakowski J: Przypadek Choroby Fahra u pacjentki z 
objawami depresji endogennej. Psychiatro Pol, 1988; 4: 341–43 [in 
Polish]
 38. Seidler GH: Psychiatric and psychological aspects of Fahr syndrome. 
Psychiatr Prax, 1985; 12: 203–5
 39. Mufaddel AA, Al-Hassani GA: Familial idiopathic basal ganglia 
calcification (Fahr’s disease). Neurosciences (Riyadh), 2014; 19: 
171–77
 40. Simone O, Tortorella C, Antonaci G, Antonaci S: [An unusual case of 
transient loss of consciousness: the Fahr’s syndrome]. Recenti Prog 
Med, 2008; 99: 93–96 [in Italian]
 41. Tuglu D, Yuvanç E, Bal F et al: Fahr syndrome unknown 
complication: Overactive bladder. Case Rep Urol, 2014; 2014: 939268
 42. Virchow R: Kark-Metastasen. Virchows Arch Pathol Anat, 1955; 8: 
103–13
 43. Kozic D, Todorovic-Djilas L, Semnic R et al: MR imaging – an 
unreliable and potentially misleading diagnostic modality in 
patients with intracerebral calcium depositions. Case report. Neuro 
Endocrinol Lett, 2009; 30: 553–57
 44. Sahin N, Solak A, Genc B, Kulu U: Fahr disease: Use of susceptibility-
weighted imaging for diagnostic dilemma with magnetic resonance 
imaging. Quant Imaging Med Surg, 2015; 5(4): 628–32
 45. Toscano M, Canevelli M, Giacomelli E et al: Transcranial sonography 
of basal ganglia calcifications in Fahr disease. J Ultrasound Med, 
2011; 30: 1032–33
 46. Awrachami E, Cohn DF, Feibel M, Tadmor R: MRI demonstration and 
CT correlation of the brain in patients with idiopathic intracerebral 
calcification. J Neurol, 1994; 241: 381–84
 47. Schmid H, Haller R, König P: [Value of EEG in parathyroid gland 
disorders and/or symmetrical calcinosis of the basal ganglia (Fahr 
syndrome). Review of the literature with personal cases.] Wien Klin 
Wochenschr, 1986; 98: 486–90 [in German]
 48. Moskowitz MA, Winickoff RN, Heinz ER: Familial calcification of the 
basal ganglions: a metabolic and genetic study. N Engl J Med, 1971; 
285(2): 72–77
 49. Ellie E, Julien J, Ferrer X: Familial idiopathic striopallidodentate 
calcifications. Neurology, 1989; 39(3): 381–85
 50. Manyam BV: What is and what is not ‘Fahr’s disease’. Parkinsonism 
Relat Disord, 2005; 11(2): 73–80
	 51.	Lazăr	M,	Ion	DA,	Streinu-Cercel	A,	Bădărău	AI:	Fahr’s	syndrome:	
Diagnosis issues in patients with unknown family history of disease. 
Rom J Morphol Embryol, 2009; 50(3): 425–28
 52. Klawans HL, Lupton M, Simon L: Calcification of the basal ganglia 




© Pol J Radiol, 2017; 82: 490-493
